Chemed Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed or view top-rated stocks.

Wall Street analysts have given Chemed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Chemed saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 196,500 shares, an increase of 45.2% from the February 28th total of 135,300 shares. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.3% of the shares of the company are short sold.
View Chemed's Short Interest.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Chemed.

Chemed will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemed Co. (NYSE:CHE) issued its quarterly earnings results on Monday, February, 22nd. The company reported $5.13 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $5.13. The company had revenue of $533 million for the quarter, compared to analysts' expectations of $537.20 million. Chemed had a trailing twelve-month return on equity of 38.13% and a net margin of 13.11%. The business's revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the company posted $4.22 EPS.
View Chemed's earnings history.

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHE shares have increased by 14.2% and is now trading at $472.66.
View which stocks have been most impacted by COVID-19.

Chemed declared a quarterly dividend on Friday, February 19th. Shareholders of record on Monday, March 1st will be given a dividend of $0.34 per share on Friday, March 19th. This represents a $1.36 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Friday, February 26th.
View Chemed's dividend history.

Chemed pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.28%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 9.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.51% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

Chemed issued an update on its FY21 earnings guidance on Tuesday, February, 23rd. The company provided earnings per share guidance of $17.00-17.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.28.

1 Wall Street analysts have issued 12-month price targets for Chemed's shares. Their forecasts range from $580.00 to $580.00. On average, they anticipate Chemed's stock price to reach $580.00 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts' price targets for Chemed or view top-rated stocks among Wall Street analysts.

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of CHE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.97%), Boston Trust Walden Corp (0.63%), Retirement Systems of Alabama (0.24%), Cabot Wealth Management Inc. (0.14%), New York State Teachers Retirement System (0.14%) and Contravisory Investment Management Inc. (0.06%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, New York State Teachers Retirement System, Hillsdale Investment Management Inc., Hexavest Inc., Contravisory Investment Management Inc., BOKF NA, Venturi Wealth Management LLC, and IBM Retirement Fund. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed or view top insider-selling stocks.

CHE stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Cabot Wealth Management Inc., State of Alaska Department of Revenue, TrimTabs Asset Management LLC, Capital Insight Partners LLC, LVW Advisors LLC, Louisiana State Employees Retirement System, and GPS Wealth Strategies Group LLC.
View insider buying and selling activity for Chemed or or view top insider-buying stocks.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $472.66.

Chemed has a market capitalization of $7.55 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis.

Chemed employs 15,544 workers across the globe.

Chemed was founded in 1970.

The official website for Chemed is www.chemed.com.

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.